Satellos Bioscience Inc News - MSCL | Aktien Toronto Börse

Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

- Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration - Phase 1a...

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

- Satellos plans to highlight Phase 1 safety and PK data for SAT-3247 Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the...

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

- Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy...

Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule...

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

- Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study - Up to 10 adult...

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to...

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule...

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule...

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no...

Satellos to Participate in November 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule...

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps...

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in...

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule...

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”...

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Satellos Bioscience Inc (MSCL)

Professionelle Tools für Privatanleger.

MSCL Nachrichten

Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

Satellos to Participate in November 2024 Investor Conferences

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

MSCL Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Satellos Bioscience Inc (MSCL) News

Satellos Bioscience Inc (MSCL)

Professionelle Tools für Privatanleger.

MSCL Nachrichten

Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

Satellos to Participate in November 2024 Investor Conferences

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

MSCL Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen